← Eichor
Condition: Myasthenia Gravis Generalized Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Myasthenia Gravis Generalized

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

PANORAMA: Neuromuscular Organoids for Refractory AChR+ Myasthenia Gravis
Phase N/A · 1 location(s) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · NCT07717281Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis
Phase N/A · 23 location(s) · Alexion Pharmaceuticals, Inc. · NCT06967480Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis
Phase N/A · 12 location(s) · AstraZeneca · NCT06909253Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myast
Phase 3 · 145 location(s) · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of M · NCT06463587A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
Phase 2/Phase 3 · 9 location(s) · UCB Biopharma SRL · NCT06055959ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With
Phase 2 · 15 location(s) · argenx · NCT07284420A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Disease
Phase 1 · 13 location(s) · Arcellx, Inc. · NCT06626919Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
Phase N/A · 7 location(s) · Alexion Pharmaceuticals, Inc. · NCT06312644A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
Phase 2/Phase 3 · 19 location(s) · Janssen Research & Development, LLC · NCT05265273Study of Aritinercept in Patients With Generalized Myasthenia Gravis
Phase 1/Phase 2 · 3 location(s) · Aurinia Pharmaceuticals Inc. · NCT07596901PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
Phase 3 · 13 location(s) · Alexion Pharmaceuticals, Inc. · NCT06607627Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis
Phase 1/Phase 2 · 11 location(s) · Novartis Pharmaceuticals · NCT06704269Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research
Phase N/A · 1 location(s) · Brain Inflammation Collaborative · NCT04806620A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Gener
Phase 3 · 129 location(s) · Novartis Pharmaceuticals · NCT06744920Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myastheni
Phase 4 · 12 location(s) · UCB Biopharma SRL · NCT07246564Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis
Phase 3 · 34 location(s) · Cartesian Therapeutics · NCT06799247Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
Phase N/A · 51 location(s) · Alexion Pharmaceuticals, Inc. · NCT04202341A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
Phase 2 · 24 location(s) · Vertex Pharmaceuticals Incorporated · NCT07501702Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis
Phase 1 · 1 location(s) · Ting Chang, MD · NCT06371040Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Myasthenia Gravis
NA · 2 location(s) · University of Missouri-Columbia · NCT06064695A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
Phase 2/Phase 3 · 18 location(s) · Shanghai Jiaolian Drug Research and Development Co., Ltd · NCT06447597Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
Phase 3 · 84 location(s) · Immunovant Sciences GmbH · NCT07039916ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Particip
Phase N/A · 18 location(s) · argenx · NCT07294170Zilucoplan for Severe gMG Exacerbations
Phase 3 · 1 location(s) · Miriam Freimer · NCT07215949Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Phase N/A · 2 location(s) · Sanford Health · NCT01793168GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)
EARLY_Phase 1 · 1 location(s) · Daishi Tian · NCT07058298Markers of Favorable Response to FcRn Inhibitors(INFORM)
Phase N/A · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT06685055Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
Phase 3 · 15 location(s) · Janssen Research & Development, LLC · NCT07217587Rituximab EfFicacy IN MyasthEnia Gravis (REFINE)
Phase 3 · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT05868837A Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized M
Phase 1 · 1 location(s) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · NCT06688435
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.